Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of revenue | 49,648 | 45,117 |
| Gross profit | 21,490 | 28,346 |
| Operating expenses | ||
| Research and development | 14,176 | 12,395 |
| Selling and marketing | 12,221 | 8,465 |
| General and administrative | 27,684 | 25,291 |
| Amortization of intangible assets | 2,031 | 1,990 |
| Total operating expenses | 56,112 | 48,141 |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s R&D?
- Fulgent Genetics, Inc. (FLGT) reported R&D of $14.18M in Q1 2026.
- How has Fulgent Genetics, Inc.'s R&D changed year-over-year?
- Fulgent Genetics, Inc.'s R&D increased by 14.4% year-over-year, from $12.4M to $14.18M.
- What is the long-term trend for Fulgent Genetics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s R&D has grown at a 22.1% compound annual growth rate (CAGR), from $24.22M to $53.91M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Fulgent Genetics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude